<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="publisher">pmed</journal-id><journal-id journal-id-type="flc">plme</journal-id><journal-id journal-id-type="nlm-ta">PLoS Med</journal-id><journal-id journal-id-type="pmc">plosmed</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Medicine</journal-title></journal-title-group><issn pub-type="ppub">1549-1277</issn><issn pub-type="epub">1549-1676</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="doi">10.1371/journal.pmed.0030538</article-id><article-id pub-id-type="publisher-id">06-PLME-C-0903</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Correspondence</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Infectious Diseases</subject>
          <subject>Infectious Diseases</subject>
          <subject>Non-Clinical Medicine</subject>
          <subject>Public Health and Epidemiology</subject>
          <subject>Science Policy</subject>
        </subj-group>
        <subj-group subj-group-type="System Taxonomy">
          <subject>HIV Infection/AIDS</subject>
          <subject>Medicine in Developing Countries</subject>
          <subject>Public Health</subject>
          <subject>Resource allocation and rationing</subject>
        </subj-group>
      </article-categories><title-group><article-title>HIV-1 Viral Load Assays for Resource-Limited Settings: Clades Matter</article-title><alt-title alt-title-type="running-head">Correspondence</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Preiser</surname>
            <given-names>Wolfgang</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Drexler</surname>
            <given-names>Jan Felix</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Drosten</surname>
            <given-names>Christian</given-names>
          </name>
        </contrib>
      </contrib-group><author-notes>
        <fn fn-type="current-aff" id="n3">
          <p>Wolfgang Preiser (<email xlink:type="simple">preiser@sun.ac.za</email>)</p>
        </fn>
        <fn fn-type="current-aff" id="n4">
          <p>Faculty of Health Sciences, Stellenbosch University, National Health Laboratory Service, Tygerberg, South Africa</p>
        </fn>
        <fn fn-type="current-aff" id="n5">
          <p>Jan Felix Drexler, Christian Drosten, Bernhard Nocht Institute for Tropical Medicine,  Hamburg, Germany</p>
        </fn>
      <fn fn-type="conflict" id="n2">
        <p> The authors have declared that no competing interests exist.</p>
      </fn></author-notes><pub-date pub-type="ppub">
        <month>12</month>
        <year>2006</year>
      </pub-date><pub-date pub-type="epub">
        <day>26</day>
        <month>12</month>
        <year>2006</year>
      </pub-date><volume>3</volume><issue>12</issue><elocation-id>e538</elocation-id><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2006</copyright-year><copyright-holder>Preiser et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article page="e417" related-article-type="companion" vol="3" xlink:href="info:doi/10.1371/journal.pmed.0030417" xlink:title="Research in Translation" xlink:type="simple">
				<article-title>HIV-1 Viral Load Assays for Resource-Limited Settings</article-title>
			</related-article><related-article page="e550" related-article-type="companion" vol="3" xlink:href="info:doi/10.1371/journal.pmed.0030550" xlink:title="Correspondence" xlink:type="simple">
				<article-title>HIV-1 Viral Load Assays for Resource-Limited Settings: Authors' Reply </article-title>
			</related-article><funding-group><funding-statement>The authors received no specific funding for this article.</funding-statement></funding-group><counts>
        <page-count count="2"/>
      </counts><!--===== Restructure custom-meta-wrap to custom-meta-group =====--><custom-meta-group>
        <custom-meta>
          <meta-name>citation</meta-name>
          <meta-value>Preiser W, Drexler JF, Drosten C (2006) HIV-1 viral load assays for resource-limited settings: Clades matter. PLoS Med 3(12): e538. doi:<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0030538" xlink:type="simple">10.1371/journal.pmed.0030538</ext-link></meta-value>
        </custom-meta>
      </custom-meta-group></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title/>
      <p>The paper by Fiscus et al. [<xref ref-type="bibr" rid="pmed-0030538-b001">1</xref>] gives an excellent overview of current technologies to measure HIV-1 viral load (VL), and highlights the problems with finding assays that, whilst affordable and practicable, provide reliable and high-quality results to guide patient management in resource-constrained settings.</p>
      <p>One concern, which in our mind does not receive enough attention in the paper, is HIV variability. The assays' ability to reliably quantitate non-B HIV-1 subtypes and strains is of paramount importance, given the predominance of non-B HIV infections in developing countries [<xref ref-type="bibr" rid="pmed-0030538-b002">2</xref>]. Unfortunately, genotype bias has not been assessed systematically for most of the assays described in the paper.</p>
      <p>In our recent paper, “Ultrasensitive Monitoring of HIV-1 Viral Load by a Low-Cost Real-Time Reverse Transcription-PCR Assay with Internal Control for the 5' Long Terminal Repeat Domain” [<xref ref-type="bibr" rid="pmed-0030538-b003">3</xref>] (which is found by Fiscus et al.'s PubMed search strategy for “HIV-1 viral load AND resource-limited settings” but presumably just missed the deadline for [<xref ref-type="bibr" rid="pmed-0030538-b001">1</xref>]), we describe an inexpensive assay targeting the conserved long terminal repeat (LTR) domain of HIV-1.</p>
      <p>In addition to comparing the assay with three commercial tests using patient samples from Brazil, South Africa, India, and Germany, we also extensively determined its ability to accurately quantitate different HIV-1 subtypes. For this we used two HIV-1 subtype reference panels (National Institute for Biological Standards and Control: HIV-1 M subtypes A, B, C, D, circulating recombinant form [CRF] AE, F, G, H, and HIV-1 N and O; German National Reference Centre for Retroviruses: HIV-1 M subtypes A, B, C, D [2 samples], CRF AE, F, G, and HIV-1 O [2 samples]), as well as 12 plasma samples from patients infected with non-B subtypes, including genotypes not present in the reference panels, e.g., CRFs AE and AG and subtype J, as determined by sequence analysis.</p>
      <p>We demonstrated that LTR is highly suitable for the quantification of “exotic” HIV-1 genotypes: For all genotypes, except for groups N and O, the overall results of virus quantification using different assays were highly concordant. For HIV-1 M clades and CRFs, the differences between our assay and the Roche Monitor assay were below 0.5 log; this excellent comparability between the assays is clinically acceptable. The reduced risk of genotype bias makes monitoring of HIV-1 VL feasible, to improve individual patient management as well as hopefully delay the emergence and spread of antiretroviral drug resistance.</p>
      <p>Our test is at least as good as commercial tests with regard to performance and technical features: The internal control allows recognition of inhibition and thus falsely low or negative results; its accuracy at least equals that of commercial assays; its analytical sensitivity (down to 32 copies/ml according to industry-agreed evaluation procedures including probit analysis) and broad quantification range are sufficient for both treated and untreated patients; and it is much cheaper than comparable commercial assays—less than US$10 for reagents per sample and below US$20, including the service licence payable to Roche. Its only disadvantage is that it still requires relatively expensive equipment, a certain infrastructure, and skilled personnel. Large-scale feasibility studies have commenced in Brazil, and Stellenbosch University in South Africa is going to set up the assay for viral load testing.</p>
      <p>Given the large and sadly still rapidly increasing populations of HIV-1-infected individuals in many resource-constrained countries, together with the drive to provide universal access to antiretroviral treatment and the looming danger of antiretroviral drug resistance as a significant public health problem jeopardising the success of antiretroviral treatment programmes [<xref ref-type="bibr" rid="pmed-0030538-b004">4</xref>,<xref ref-type="bibr" rid="pmed-0030538-b005">5</xref>], the potential benefit of affordable HIV-1 VL assays is enormous. The challenge lies in ensuring that these assays are adequate for the respective situation, particularly with regard to HIV-1 strain diversity.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="pmed-0030538-b001">
        <label>1</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Fiscus</surname><given-names>SA</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>B</given-names></name><name name-style="western"><surname>Crowe</surname><given-names>SM</given-names></name><name name-style="western"><surname>Demeter</surname><given-names>L</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>C</given-names></name><etal/></person-group>
					<year>2006</year>
					<article-title>HIV-1 viral load assays for resource-limited settings.</article-title>
					<source>PLoS Med</source>
					<volume>3</volume>
					<fpage>e417</fpage>
					<comment>doi:<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0030417" xlink:type="simple">10.1371/journal.pmed.0030417</ext-link></comment>
				</element-citation>
      </ref>
      <ref id="pmed-0030538-b002">
        <label>2</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Gordon</surname><given-names>M</given-names></name><name name-style="western"><surname>De Oliveira</surname><given-names>T</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>K</given-names></name><name name-style="western"><surname>Coovadia</surname><given-names>HM</given-names></name><name name-style="western"><surname>Madurai</surname><given-names>L</given-names></name><etal/></person-group>
					<year>2003</year>
					<article-title>Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from Kwazulu-Natal, South Africa: Implications for vaccine and antiretroviral control strategies.</article-title>
					<source>J Virol</source>
					<volume>77</volume>
					<fpage>2587</fpage>
					<lpage>2599</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0030538-b003">
        <label>3</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Drosten</surname><given-names>C</given-names></name><name name-style="western"><surname>Panning</surname><given-names>M</given-names></name><name name-style="western"><surname>Drexler</surname><given-names>JF</given-names></name><name name-style="western"><surname>Hansel</surname><given-names>F</given-names></name><name name-style="western"><surname>Pedroso</surname><given-names>C</given-names></name><etal/></person-group>
					<year>2006</year>
					<article-title>Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5' long terminal repeat domain.</article-title>
					<source>Clin Chem</source>
					<volume>52</volume>
					<fpage>1258</fpage>
					<lpage>1266</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0030538-b004">
        <label>4</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Wensing</surname><given-names>AM</given-names></name><name name-style="western"><surname>van de Vijver</surname><given-names>DA</given-names></name><name name-style="western"><surname>Angarano</surname><given-names>G</given-names></name><name name-style="western"><surname>Asjo</surname><given-names>B</given-names></name><name name-style="western"><surname>Balotta</surname><given-names>C</given-names></name><etal/></person-group>
					<year>2005</year>
					<article-title>Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management.</article-title>
					<source>J Infect Dis</source>
					<volume>192</volume>
					<fpage>958</fpage>
					<lpage>966</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0030538-b005">
        <label>5</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Sutthent</surname><given-names>R</given-names></name><name name-style="western"><surname>Arworn</surname><given-names>D</given-names></name><name name-style="western"><surname>Kaoriangudom</surname><given-names>S</given-names></name><name name-style="western"><surname>Chokphaibulkit</surname><given-names>K</given-names></name><name name-style="western"><surname>Chaisilwatana</surname><given-names>P</given-names></name><etal/></person-group>
					<year>2005</year>
					<article-title>HIV-1 drug resistance in Thailand: Before and after national access to antiretroviral program.</article-title>
					<source>J Clin Virol</source>
					<volume>34</volume>
					<fpage>272</fpage>
					<lpage>276</lpage>
				</element-citation>
      </ref>
    </ref-list>
    
  </back>
</article>